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2ABSTRACT29
30
Human herpesviruses are responsible for a range of debilitating acute and recurrent diseases,31
including a number of malignancies. Current treatments are limited to targeting the herpesvirus32
DNA polymerases, however with emerging viral resistance and little efficacy against the33
oncogenic herpesviruses, there is an urgent need for new antiviral strategies. Herein we34
describe a mechanism to inhibit the replication of the oncogenic herpesvirus Kaposi’s sarcoma35
associated herpesvirus (KSHV), by targeting the ATP-dependent formation of viral36
ribonucleoprotein particles (vRNPs). We demonstrate that small molecule inhibitors which37
selectively inhibit the ATPase activity of the cellular human transcription/export complex38
(hTREX) protein UAP56, result in effective inhibition of vRNP formation, viral lytic replication39
and infectious virion production. Strikingly, as all human herpesviruses utilize conserved40
mRNA processing pathways involving hTREX components, we demonstrate the feasibility of41
this approach for pan-herpesvirus inhibition.42
3Human herpesviruses are responsible for a range of acute and chronic diseases,43
including several cancers1-3. Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic44
agent of Kaposi’s sarcoma and two lymphoproliferative disorders; primary effusion lymphoma45
and multicentric Castleman's disease4. Like all herpesviruses, KSHV has two distinct forms of46
infection; latency and lytic replication. While the majority of KSHV-associated tumorigenic cells47
harbor latent virus, lytic gene expression occurs to various levels in each KSHV-associated48
disorder5-11, suggesting that lytic replication inhibition may provide therapeutic intervention.49
Currently, drugs in clinical use are inhibitors of herpesvirus DNA polymerases. These50
nucleotide, nucleoside and pyrophosphate analogues are highly effective against a variety of51
herpesviruses, although drug-resistant strains can emerge in immunocompromised patients,52
carrying mutations in genes encoding the thymidine kinase, protein kinase or DNA53
polymerase12. Moreover, varying efficacy has been reported against the oncogenic gamma-54
herpesvirus subfamily13-17. Consequently, there is an urgent need for the continued55
development of anti-herpesvirus drugs, particularly targeting oncogenic herpesviruses.56
RNA helicases contribute to remodeling of intramolecular RNA-, RNA-protein and57
protein-protein interactions in an ATP-dependent manner18. Both viral and cellular RNA58
helicases have central roles in virus life cycles and have emerged as therapeutic targets19.59
Numerous studies have evaluated the potential of targeting virally-encoded RNA helicases20-60
22
. However, to circumvent viral resistance, inhibiting cellular RNA helicases has also been61
explored, supported by efforts targeting eIF4A for the treatment of cancer and DDX3 to inhibit62
HIV replication, illustrating selective pharmacological targeting of RNA helicases is possible23-63
25
.64
The KSHV open reading frame (ORF) 57 protein, which has a functional homologue65
in each human herpesvirus, is essential for viral lytic replication26. It is a multifunctional protein66
involved in all stages of viral mRNA processing via an interaction with the human67
transcription/export (hTREX) complex27. hTREX is a large multiprotein complex involved in68
Nxf1-mediated cellular bulk mRNA nuclear export. Notably, ORF57-mediated hTREX69
recruitment produces a viral ribonucleoprotein particle (vRNP) essential for KSHV lytic70
replication28,29. ORF57 forms a direct interaction with the cellular export adapter Aly, however,71
redundancy in the cellular mRNA export pathway also allows ORF57 to facilitate vRNP72
formation via an interaction with UIF29,30. As such, disrupting the ORF57-hTREX interaction73
requires blocking multiple protein-protein interactions. Alternatively, the cellular RNA-helicase74
UAP56 functions as an essential hTREX assembly factor, forming an ATP-dependent trimeric75
complex with Aly and CIP29, as well as recruiting further hTREX components onto76
mRNAs31,32. Therefore, we examined the potential of inhibiting UAP56 ATPase activity, to77
prevent KSHV vRNP formation and lytic replication. In silico high-throughput screening78
4identified small molecules capable of binding the UAP56 ATP-binding pocket. Strikingly,79
results demonstrate that inhibiting UAP56 ATPase activity represents an antiviral target.80
5RESULTS81
82
KSHV vRNP formation is ATP-cycle dependent83
KSHV ORF57 interacts with hTREX to form an export-competent vRNP33. As the84
hTREX core component, UAP56, has RNA-stimulated ATPase activity, we assessed whether85
ATP binding/hydrolysis are required for ORF57-mediated vRNP formation. Co-86
immunoprecipitation assays were performed using lysates from HEK-293T cells transfected87
with GFP or GFP-UAP56 in the absence/presence of ORF57-mCherry, supplemented with88
1.25 mM ATP or a non-hydrolysable ATP analogue, Adenosine 5'-O-(3-thio)triphosphate89
(ATPɶS). Results showed that the ORF57-UAP56 interaction, hence vRNP formation, is ATP-90
dependent (Fig. 1a). ATP enhanced the interaction between ORF57 and endogenous hTREX91
SURWHLQV&RQYHUVHO\$73Ȗ6VLJQLILFDQWO\LQKLELWHGWKH25)8$3LQWHUDFWLRQKLJKOLJKWLQJ92
the necessity of ATP hydrolysis for vRNP formation. Notably, Aly and CIP29 binding with93
8$3ZDVXQDIIHFWHGE\$73Ȗ6DQGDVPDOOEXWVLJQLILFDQW LQFUHDVH LQELQGLQJFRXOGEH94
observed compared to controls (Fig. 1b)7KHHIIHFWRI$73DQG$73Ȗ6RQWKH8$325)95
interaction was dose-dependent (Supplementary Fig. 1a). Importantly, results suggest that96
inhibiting ATP hydrolysis prevents ORF57-mediated vRNP formation, without disrupting97
endogenous hTREX.98
 6LQFH 25)K75(; ELQGLQJ LV GLVUXSWHG E\ $73Ȗ6 ZH VSHFXODWHG WKDW 8$399
ATPase function is required for hTREX remodeling, enabling ORF57 association. Either the100
energy-generating step of ATP hydrolysis or its product, ADP, binding to UAP56 was101
responsible for the conformational change allowing ORF57 binding. Co-immunoprecipitation102
assays performed in the presence of ADP disrupted the UAP56-ORF57 interaction in a dose103
dependent manner, indicating that ATP hydrolysis is the essential factor for the ORF57-104
hTREX interaction (Fig. 1c, d; Supplementary Fig. 1b). However, ADP also disrupted105
endogenous hTREX. This data indicates an ATP-cycle dependent remodeling of hTREX106
enabling vRNP formation (Fig. 1e). Upon ATP-binding endogenous hTREX is formed, ATP-107
hydrolysis then initiates a conformational change within hTREX allowing ORF57 binding. After108
release of inorganic phosphate, bound ADP causes complex dissociation.109
110
Screening for UAP56 ATPase inhibitors111
We speculated that inhibitors targeting UAP56 ATPase activity would prevent ORF57-112
PHGLDWHG Y513 IRUPDWLRQ ,PSRUWDQWO\ $73Ȗ6EDVHG H[SHULPHQWV LQGLFDWH D SRWHQWLDO WR113
prevent vRNP formation whilst maintaining endogenous hTREX. In silico high-throughput114
screening (HTS) was utilized to identify small-molecules capable of binding the UAP56115
adenine-binding site, based on the UAP56:ADP co-crystal structure34. Favored compounds116
were tested for their potential to inhibit recombinant UAP56 ATPase activity. The most potent117
6compound, CCT018159 (Fig. 2a), reduced UAP56 activity by >70% at 100 µM. Molecular118
modeling predicted CCT018159 binds the UAP56 ADP-binding pocket, with the resorcinol119
substructure mimicking the adenine unit of ADP and the methyl group at the 5-position of the120
pyrazole ring projecting towards the phosphate channel (Fig. 2b-d). The molecule forms H-121
bonding interactions from the resorcinol hydroxyls to His67, Glu66 and Gln72 and a S-stacking122
interaction from the aryl ring to Phe65. The rest of the interactions are hydrophobic in nature123
(Met93, Gly92, Gly94 and Gly64). UAP56 inhibition was dose-dependent with non-linear124
regression determining a half maximal inhibitory concentration (IC50RIȝ0PHDQ125
± s.e.m.) (Fig. 2e).126
CCT018159 has previously been identified by HTS as a heat shock protein 90 (HSP90)127
inhibitor35, we therefore calculated the inhibitory constant (Ki) comparing affinities towards128
UAP56 and HSP90, a value which takes enzyme and substrate concentrations utilized in129
biochemical assays into account. Employing the published KM value for UAP56 ATP binding36,130
we calculated a Ki value of 5.5 ± 0.2 µM for CCT018159, similar to the reported Ki of 1.8 ±131
0.3 µM of CCT018159 against HSP9037. To examine the specificity of CCT018159 against132
UAP56, we utilized 17-DMAG, an alternative HSP90 inhibitor, but found no UAP56 ATPase133
inhibition (Supplementary Fig. 2a). Microscale thermophoresis also confirmed CCT018159-134
UAP56 binding (Fig. 2f, Supplementary Fig. 2b, c), yielding a KDRIȝ0LQGLFDWLQJ135
relatively weak binding in a similar range to its natural substrate, ATP (KD ȝ0136
Finally, using an ADP-displacement assay, we confirmed that CTT018159 is an ATP/ADP-137
competitive inhibitor binding in the UAP56 adenine-binding pocket (Fig. 2g). Notably, these138
assays used recombinant UAP56 in the absence of any cellular co-factors, apart from RNA,139
which may affect the CCT018159-UAP56 binding affinity, as shown for hTREX components140
stimulating UAP56 ATPase activity32.141
142
CCT018159 disrupts vRNP formation without inhibiting cellular mRNA export143
The effect of CCT018159 on vRNP formation was assessed using co-144
immunoprecipitation assays. MTS assays identified non-cytotoxic concentrations in HEK-145
293T cells, < 15 µM (Fig. 3a). Cells were transfected with GFP or ORF57-GFP, then incubated146
in the absence/presence of a concentration series of CCT018159. After 24 h, co-147
immunoprecipitations were performed using an UAP56-specific antibody, again in the148
absence/presence of CCT018159. CCT018159 effectively reduced the ORF57-UAP56149
interaction at 2.5 and 5 µM concentrations, whilst maintaining endogenous hTREX formation150
(Fig. 3b, Supplementary Fig. 3a). Furthermore, up to 0.5 mM CCT018159 added to the lysate151
did not inhibit the hTREX-UAP56 interaction. To confirm UAP56-specific inhibition, co-152
immunoprecipitations were repeated in absence/presence of a concentration range of153
17-DMAG showing minimal cytotoxicity (Supplementary Fig. 3b, c). Encouragingly, the154
7ORF57-UAP56 interaction was not disrupted, indicating that CCT018159-mediated vRNP155
disruption is due to UAP56 inhibition. Additionally, ORF57-mediated nucleolar redistribution of156
hTREX components was also assessed38. CIP29 localizes to the nuclear speckles excluding157
the nucleolus, however, upon ORF57 expression CIP29 is redistributed and co-localizes with158
nucleolar ORF5739. Conversely in CCT018159-treated cells, ORF57 failed to redistribute159
CIP29 to the nucleolus, with both proteins localizing independently in the nuclear speckles160
(Supplementary Fig. 3d).161
Following effective vRNP disruption in vitro and in cell culture, we examined the effect162
of CCT018159 on ORF57-mediated mRNA processing. Cells were transfected with GFP or163
ORF57-GFP and a viral intronless ORF47 mRNA reporter construct, then treated with DMSO164
or CCT018159 for 18 h and ORF47 mRNA levels assessed in whole cell and cytoplasmic165
lysates (Fig. 3c). The ORF57-hTREX interaction stabilizes viral mRNAs allowing enhanced166
viral mRNA export40, and results confirmed an increase in whole cell and cytoplasmic ORF47167
mRNA abundance. In contrast, CCT018159 abolished both stabilization and ORF47 mRNA168
export, with no significant difference over GFP-transfected controls. Together, data suggest169
that CCT018159 prevents the vRNP formation and downstream mRNA processing.170
ORF57-hTREX binding results in a block of cellular bulk mRNA nuclear export11.171
Therefore, if CCT018159 disrupts ORF57-mediated vRNP formation without affecting172
endogenous hTREX, cellular bulk mRNA export should be restored. Fluorescence in situ173
hybridization (FISH) was used to monitor cellular bulk mRNA export (Fig. 3d). In GFP-174
expressing cells, the majority of polyadenylated RNA (poly(A)-RNA) was detected in the175
cytoplasm with minor amounts in nuclear speckles. However, ORF57-mediated hTREX176
sequestration led to a marked reduction of cytoplasmic poly(A)-RNA and retention in the177
nucleus. Strikingly, in ORF57-expressing cells treated with CCT018159, nuclear retention was178
lost, with poly(A)-RNA present in the cytoplasm. Quantification of the FISH analysis showed179
this effect to be significant (Fig. 3e). Importantly, results demonstrated that CCT018159 does180
not affect endogenous hTREX. Results were confirmed by qRT-PCR analysis, measuring the181
export of selected cellular mRNAs in the absence/presence of CCT018159 (Supplementary182
Fig. 3e). FISH analysis was repeated in the presence of 17-DMAG, which failed to relieve183
ORF57-mediated nuclear retention of cellular bulk mRNA (Supplementary Fig. 3f, g). This184
confirms CCT018159-mediated UAP56 inhibition independent of HSP90.185
186
CCT018159 prevents KSHV lytic replication187
ORF57-mediated vRNP formation is essential for KSHV lytic replication33. Therefore,188
we examined the potential of CCT018159 to inhibit KSHV replication using the KSHV-infected189
cell line TREx BCBL1-Rta41. MTS assays and non-linear regression determined the cytotoxic190
concentration 50 (CC50) for 24 and 72 h time points (Fig. 4a, b). Furthermore, no increase in191
8DSRSWRVLVZDVREVHUYHGDW ȝ0&&7 (Supplementary Fig. 4a), contrary to the192
observed effect of HSP90 inhibitors in KSHV-infected cell lines42,43. TREx BCBL1-Rta cells193
remained latent or were reactivated with doxycycline and treated with increasing amounts of194
CCT018159. Immunoblotting using Myc and ORF57-specific antibodies (markers for induction195
of lytic replication) or the KSHV minor capsid protein (mCP)-specific antibody (viral lytic late196
protein dependent on vRNP assembly) showed a marked reduction in mCP expression at197
ȝ0 &&7 (Fig. 4c; Supplementary Fig. 4b), whereas no decrease in ORF57198
expression is noted, confirming the decrease in mCP expression is not due to loss of ORF57199
or lower reactivation levels (Supplementary Figure 4b, c). Moreover, ORF57 is translated200
from an intron-containing transcript, indicating functional hTREX. Quantification and non-linear201
regression of mCP levels obtained an effective concentration 50 (EC50) for viral protein202
expression. Importantly, the EC50RIȝ0LVIDUORZHUWKDQWKH&&50RIȝ0DWWKLVWLPH203
point. A large “therapeutic window” is observed, showing that cytotoxicity occurred at higher204
concentrations than inhibition of viral protein expression (Fig. 4c).205
To assess whether CCT018159 also decreased viral genome replication and virion206
production, uninduced or reactivated TREx BCBL1-Rta cells were treated with increasing207
amounts of CCT018159 and qPCR used to determine viral load. A steep decrease in viral load208
ZDVYLVLEOHDWDQGȝ0&&7(Fig. 4d). Non-linear regression calculated an EC50209
RQYLUDO UHSOLFDWLRQRIȝ0$JDLQZKHQFRPSDUHGWRWKHK&&50RIȝ0D ODUJH210
“therapeutic window” was observed. This concentration range produced dramatic inhibition of211
viral replication without any cytotoxicity. To examine virion production, supernatants were212
used to re-infect naïve cells and qRT-PCR determined KSHV gene expression. Cells213
re-infected with supernatant from CCT018159-treated cells contained 80% less viral mRNA214
than controls (Fig. 4e). Together results suggest that CCT018159 is effective at inhibiting215
KSHV lytic replication and virion production.216
To confirm CCT018159-mediated inhibition of KSHV replication is due to vRNP217
disruption and not HSP90 inhibition, we performed MTS and viral load assays using218
17-DMAG. While a therapeutic window was observed, CC50RIȝ0DQG(&50 of 0.04219
ȝ0(Supplementary Fig. 4d), we noticed irregularities for both assays. The metabolic220
activity, reflecting cell viability, was initially increased, before decreasing at higher221
concentrations. This 17-DMAG-induced cellular stress resulted in increased levels of222
apoptosis and necrosis (Supplementary Fig. 4e). This was in contrast to CCT018159, but223
reflects published results showing HSP90 inhibitors cause apoptosis43,44, via vFLIP224
GHJUDGDWLRQ DQG VXEVHTXHQW GRZQUHJXODWLRQ RI 1)ț% VLJQDOLQJ SDWKZD\43,44. Importantly,225
1)ț%VLJQDOLQJLVVLJQLILFDQWO\UHGXFHGLQ'0$*WUHDWHGFHOOVFRPSDUHGWR&&7226
(Supplementary Fig. 4f). Moreover, a decrease in viral load upon 17-DMAG treatment not227
only indicated a block in lytic reactivation, but also viral episome loss via KSHV latent nuclear228
9antigen (LANA) degradation42. Immunoblotting showed enhanced LANA and CDC2229
degradation in the presence of 17-DMAG (Supplementary Fig. 4g), whereas no LANA230
degradation was observed for a range of concentrations of CCT018159, although CDC2 levels231
were reduced from 5 µM. Notably, KSHV mCP inhibition occurred at concentrations of 1–232
2.5 µM CCT018159 (Supplementary Fig. 5a-c). This data confirms that CCT018159-233
mediated inhibition is due to vRNP disruption, not HSP90-related inhibitory mechanisms.234
235
Effect of CCT018159 structural analogues on KSHV replication236
To assess a structure-activity-relationship, 4 structural analogues of CCT018159 were237
analyzed (Table 1; Supplementary Fig. 6-9). An IC50 was determined for all analogues238
against recombinant UAP56 in vitro. The CC50 on TREx BCBL1-Rta cells was assessed by239
MTS assay and the inhibitory potential (EC50) on viral protein production and genome load240
also determined. Furthermore, immunoprecipitations were employed to test those compounds241
effective against KSHV lytic replication for their ability to disrupt the UAP56-ORF57 interaction242
(Supplementary Fig. 6f, 7f, 8f). All analogues present minor structural variations on243
CCT018159 at the 2,4-hydroxyphenyl, benzodioxanyl and pyrazole subsites. Removal of the244
ethyl group at the resorcinol substructure (Compound 2) was not detrimental to activity and245
showed similar inhibitory effects on KSHV replication, consistent with molecular modelling in246
which the ethyl group extends into solvent (Fig. 2d). Replacement of the methyl group at the247
5-position of the pyrazole ring with a carboxylic acid (Compound 4) ablated any inhibitory248
activity, suggesting the carboxylate group is not tolerated at the entrance to the phosphate249
channel, possibly due to its charged nature and relative proximity to two carbonyl groups (Gly-250
92, Thr-96) inducing a repulsive interaction. Supportive of this hypothesis, re-docking of the251
compound failed to generate a binding pose. Replacement of the dioxanyl ring with a methoxy252
group (Compound 3) and H (Compound 1) demonstrated a modest reduction of ATPase253
activity and KSHV inhibition, consistent with molecular modeling demonstrating a reduced254
potential for hydrophobic contact to the side-chain of Met93. The analogues were also tested255
for HSP90 inhibition. Notably, combining results with virus inhibition, a larger therapeutic256
window was observed for Compound 1 (Supplementary Fig. 10a-c). CDC2 expression was257
FRQVWDQW EHORZ  ȝ0 ZKHUHDV HIIHFWLYH P&3 LQKLELWLRQ RFFXUUHG EHWZHHQ ± ȝ0258
&RPSRXQGVKRZHGDPDUNHGGHFUHDVHLQH[SUHVVLRQIRUERWKP&3DQG&'&DWȝ0259
suggesting an efficient HSP90 inhibitor (Supplementary Fig. 11a-c). Therefore distinct260
responses were observed for all compounds, with CCT018159 and Compound 1 showing261
specifically inhibition of virus replication by inhibiting UAP56.262
263
&&7LQKLELWVĮDQGȕKHUSHVYLUXVUHSOLFDWLRQ264
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All herpesviruses encode an ORF57 homologue which utilizes hTREX components for265
vRNP assembly. To examine any potential pan-herpesvirus activity, we assessed the266
LQKLELWRU\ HIIHFW RI &&7 RQ WKH Į DQG ȕKHUSHVYLUXVHV +69 DQG +&09267
respectively. First, immunoprecipitations of UAP56 were repeated in the presence of the268
ORF57 homologues, HSV-1 ICP27 and HCMV UL69 (Fig. 5a, b). Notably, CCT018159269
reduced the interaction of both viral proteins and hTREX to a similar level observed for ORF57.270
Further, a non-cytotoxic working concentration of CCT018159 in HFF cells was determined271
(Fig. 5c, d), cells were then infected with HSV-1, prior to treatment with increasing amounts272
of CCT018159. Cells were directly imaged for HSV-mediated cell lysis (Supplementary Fig.273
12a) or assessed using a plaque assay (Fig. 5e). Strikingly, with CCT018159 increasing274
concentrations, cell lysis, plaque size and plaque number was dramatically decreased,275
demonstrating efficient inhibition of HSV-1 replication. Moreover, a marked reduction in virion276
production was observed after re-infection with the harvested supernatant and assessment by277
flow cytometry (Fig. 5f; Supplementary Fig. 12b), plaque assay (Fig. 5g) and immunoblotting278
of the lytic protein, ICP27 (Supplementary Fig. 12c)ȝ0&&7UHVXOWHGLQD279
UHGXFWLRQLQLQIHFWHGFHOOVZLWKDUHGXFWLRQREVHUYHGDWȝ0&&7280
Inhibition of HCMV lytic replication was assessed after infection of HFF cells and281
treatment with CCT018159. Cells were directly imaged for HCMV-mediated cell lysis282
(Supplementary Fig. 12d) and re-infection levels were quantified by qPCR (Fig. 5h).283
Excitingly, 1 µM CCT018159 was found to reduce HCMV virion production by 50%, with over284
99% reduction at 2.5 µM. Importantly, a 90% reduction of infectious HSV-1 or HCMV virion285
SURGXFWLRQZDVGHWHUPLQHGDWRUȝ0&&7ZKHUHQRLQKLELWLRQRI+63RFFXUUHG286
(Supplementary Fig. 13a-c), providing a clear therapeutic window. Together, these results287
show that CCT018159 has pan-herpesvirus activity.288
11
DISCUSSION289
Disrupting the ORF57-hTREX interaction is an antiviral target, however, strategies to290
block this interaction are complicated by redundancy in the mammalian mRNA export291
system29. Consequently we targeted the ATP-cycle dependent remodeling of hTREX required292
for vRNP formation. The UAP56 ATP-binding site is situated in a cleft between two connected293
helicase domains34,45, with ATP-binding believed to bring these domains closer, enabling a294
closed conformation. Therefore, we speculate that inhibiting ATP hydrolysis traps UAP56 in295
the ATP-bound state allowing hTREX formation, however, further remodeling is required to296
accommodate the ORF57 protein. Interestingly, ATP hydrolysis-induced conformational297
changes in DEAD-box helicases are essential during RNA unwinding18 and members of the298
exon junction complex (EJC) stabilize the post-hydrolysis state of eIF4III, trapping the protein299
onto RNA46. As ATP hydrolysis and hTREX remodeling is also necessary for Aly loading onto300
mRNA32, we hypothesize this remodeling enables ORF57 binding.301
Molecular modelling predicts CCT018159 binds the UAP56 adenine-binding pocket,302
suggesting an ATP-competitive inhibitor. While CCT018159 was found to inhibit purified303
UAP56 and displace ADP with an IC50 of about 60 µM, its antiviral effect was detected at 30-304
fold higher potency (around 2 µM). As it has previously been shown that hTREX proteins Aly305
and CIP29 stimulate UAP56 ATP binding and hydrolysis31, it is not surprising that the affinity306
of UAP56 for CCT018159 should also change in the presence of cellular co-factors. Although307
CCT018159 is a known HSP90 inhibitor35, demonstrating complex pharmacokinetics,308
including relatively high metabolic turnover, its favorable selectivity profile against closely309
related ATPases and a panel of kinases37,47 make it a useful starting point for lead compound310
development. Data conclusively shows CCT018159-mediated UAP56 inhibition, disruption of311
the ORF57-hTREX interaction and lytic replication, with a differing phenotype from the HSP90-312
inhibitor, 17-DMAG. Nonetheless, as CCT018159-mediated HSP90 inhibition occurred at313
higher concentrations, restricting the therapeutic window, CCT018159 should be seen as a314
proof-of-principle and starting point for the development of UAP56-specific antivirals. We have315
identified analogues which demonstrate altered HSP90 inhibition, an important selection316
criterion for lead-generation UAP56 inhibitors. Future work will explore potential enhanced317
potency via extension into the phosphate channel.318
Targeting a cellular RNA helicase can be assumed to reduce the risk for virus319
resistance and theoretically provides pan-viral activity. Notably, all herpesviruses encode320
ORF57 homologues and hTREX interactions are essential for their replication33,48,49.321
Excitingly, CCT018159 prevents replication of all three herpesvirus subfamilies, indicating322
possible pan-herpesviral activity and may have wider utilization, as other important human323
pathogens co-opt UAP56 for viral mRNA processing50.324
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METHODS342
343
Virtual high-throughput screening. Identification of UAP56 ATPase inhibitors was344
performed using virtual high-throughput screening of a University of Leeds proprietary 250k345
library of small molecules selected from the ZINC database51, based on high structural346
diversity, adherence to Lipinski criteria and absence of pan interference (PAIN) scaffolds.347
Docking routines were performed using eHiTS (SymBioSys Inc.) and AutoDock4 (Scripps348
Research Institute) based on the UAP56'9 MgADP complex (1XTJ). Prior to docking ADP,349
Mg and the water molecules were removed and the protein prepared using the default settings350
within the Protein Preparation Wizard within Maestro9.4 (Schrödinger). eHiTS was used to351
screen the 250k library using a clip file generated around the ATP binding site and highest352
speed docking (accuracy mode 1). The 5k compounds which demonstrated the best eHiTS353
score based on the default scoring function with the software were re-docked using354
AutoDock4. Favored compounds (400) were selected for screening based on the default355
AutoDock4 scoring function and visualized for quality of binding mode and for compliance with356
attractive physicochemical properties (Lipinski’s rules) and availability.357
358
ATPase assay and compound screening. )RUWKH8$3$73DVHDVVD\ȝ0SXULILHG359
*678$3DQGZKHUHDSSOLFDEOH*67ZHUHLQFXEDWHGZLWKȝ0\HDVWW51$ȝ0$73360
2 mM MgCl2 and 50 mM KCl in 50 mM Tris/HCl (pH 7.6). During compound screening,361
LQKLELWRUV ZHUH DGGHG WR JLYH ILQDO FRQFHQWUDWLRQV RI ȝ0 )RU ,&50 measurements,362
FRPSRXQGVRIYDU\LQJFRQFHQWUDWLRQVZHUHGHOLYHUHG LQȝO'062RI WRWDO UHDFWLRQ363
volume). Reactions were incubated at 37°C for 30 min, before Kinase-Glo® Reagent364
(Promega) was added according to the manufacturer’s instructions to quantify remaining ATP365
by luminescence. All replicates were of biological nature.366
367
ADP displacement assay. To assess competitive binding of CCT018159 to UAP56, an368
$73DVHDVVD\DVGHVFULEHGDERYHFRQWDLQLQJȝ08$3*67DQGȝ0$73ZDVUXQIRU369
30 mins, to ensure all UAP56 was bound to ADP. Using an ADP-GloTM Kinase assay kit370
(Promega) following the manufacturer’s instructions, any remaining ATP was depleted, before371
CCT018159 was added in increasing concentrations and the reaction mixture was incubated372
at 37°C for 30 mins. Using the kit’s reagents, all free ADP was converted to ATP and quantified373
by luminescence. All replicates were of biological nature.374
375
Viral mRNA export assay. HEK-293T cells were co-transfected with GFP or ORF57-GFP376
and ORF47 expression constructs before subcellular fractionation. Quantitative qRT-PCR was377
performed on isolated RNA. Levels of the reporter mRNA ORF47 were normalized to GAPDH378
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and used to quantify viral mRNA export. The method has been described previously29,38. All379
replicates were of biological nature.380
381
Fluorescence in situ hybridization. HEK-293T cells were transfected with GFP or ORF57-382
GFP for 6 h and subsequently treated with DMSO, CCT018159 or 17-DMAG for 24 h.383
Polyadenylated RNA was detected in with an oligo dT(70) probe labeled at the 5’ end with384
Alexa Fluor 546 NHS Ester. The method was performed as published previously31. Cells were385
visualized on a Zeiss LSM 700 laser scanning confocal microscope and images analyzed386
using Zen® 2011 (Zeiss).387
388
Infectious KSHV virion production. TREx BCBL1-Rta cells were harvested 72 h after389
reactivation of viral lytic replication. Filtered tissue culture supernatants were used 1:1 to390
inoculate 1×106 HEK-293T cells. Infected cells were quantified at 24 h post-infection by real-391
time qRT-PCR. RNA was extracted from total cell lysates using TRIzol (Invitrogen) as392
described by the manufacturer. RNA was DNase treated using the Ambion® DNase-freeTM393
'1$UHPRYDONLWDVSHUWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVDQG51$ȝJIURPHDFKIUDFWLRQ394
was reverse transcribed with M-MuLV Reverse Transcriptase (New England Biolabs, Inc.), as395
per the manufacturer’s instructions, using oligo(dT) primers (Sigma-Aldrich®). Obtained cDNA396
served as template for qPCR reactions using ORF47, ORF57 and GAPDH specific primers as397
described before. Replicates were of biological nature, with each used for 2 technical repeats.398
399
Plasmids and antibodies. pGST-UAP56, pEGFP-UAP56, pORF47, pORF57-EGFP and400
pORF57-mCherry have been described previously30,31,33,52. pEGFP-N1 expressing eGFP401
(Clontech) and pGEX-4T.1 expressing GST (GE Healthcare) are commercially available.402
Antibodies against Aly (11G5) (Sigma-Aldrich®), GAPDH (6C5) (Abcam®), GFP (JL-8)403
(Clontech), ORF57 (207.6) (Santa Cruz Biotech®), UAP56 (rabbit polyclonal) (Abcam®),404
CHTOP (rabbit polyclonal) (Bethyl Laboratories, Inc.), mCP (sheep polyclonal) (Exalpha405
Biological, Inc.), CDC2 (A17) (Abcam®), HSP90 (4F10) (Santa Cruz Biotech®), LANA (13B10)406
(Leica Biosystems) and ICP27 (vP-20) (Santa Cruz Biotech®) were obtained from the407
respective companies. CIP29 antibody was a kind gift from Stuart Wilson (University of408
Sheffield)31. In general, antibodies were used for western blot analysis at a concentration of409
1:5000, ORF57, ICP27, HSP90 and mCP were used at a 1:1000 dilution, CIP29 was used at410
a 1:2500 dilution.411
412
Cell culture and viruses. HEK-293T were purchased from the ATCC (American Type Culture413
Collection) and HFF were a kind gift of John Sinclair (University of Cambridge). Both cell lines414
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were cultured in Dulbecco's modified Eagle’s medium with glutamine (DMEM, Lonza)415
supplemented with 10% foetal calf serum (FCS, Gibco®) and 1% penicillin-streptomycin416
(Gibco®). TREx BCBL1-Rta cells, a human B-cell lymphoma cell line latently infected with417
KSHV and modified to contain doxycycline (dox)-inducible myc-RTA, were a kind gift of Jae418
U. Jung (University of Southern California) (Nakamura et al, 2003). TREx BCBL1-Rta cells419
were grown in RPMI1640 growth medium with glutamine (Gibco®), supplemented with 10%420
foetal calf serum (FCS, Gibco®) and 1% penicillin-streptomycin (Gibco®). For virus421
reactivation, 0.8×106 FHOOV75([%&%/5WDFHOOVZHUH LQGXFHGXVLQJȝJPOGR[\F\FOLQH422
hyclate (Sigma-Aldrich®). Cells were harvested after 24 h for analysis of protein expression,423
while viral load and production of new infectious virions was assessed after 72 h. HCMV424
(Merlin) and HSV-1 virus (SC16) stocks were kindly provided by John Sinclair and Stacey425
Efstathiou (University of Cambridge). For each cell line a large bank of cell stocks were426
established that were used throughout the duration of the project. To reduce any impact of427
phenotypic drift, prokaryotic contamination and inadvertent cross contamination, cell cultures428
were discarded after 15 passages and new cultures established from the bank. Used cell lines429
were tested negative for Mycoplasma in 11/2014 and 01/2016.430
431
Co-immunoprecipitation assays. 1×106 HEK-293T cells were co-transfected with 1 µg of432
the indicated plasmid DNA (GFP, GFP-UAP56, ORF57-mCherry, ORF57-GFP, ICP27-GFP433
or pUL69-GFP) using Lipofectamine® 2000 according to manufacturer’s instructions434
(InvitrogenTM). Where indicated, cells were treated with CCT018159 6 h after transfection.435
After 24 h, transfected cells were lysed on ice for 20 min using 1 ml modified RIPA buffer (50436
P07ULV+&OP01D&O13DOWHUQDWLYHS+ZLWKWKHDGGLWLRQRIȝOPO51DVH437
A (InvitrogenTM). Lysates were clarified for 10 min at 16,000×g and the supernatants were pre-438
cleared against protein A beads (Roche) for 2 h at 4°C with end-over-end mixing. For the439
SUHFLSLWDWLRQV  PO RI SUHFOHDUHG O\VDWH ZDV LQFXEDWHG ZLWK  ȝO SUHZDVKHG *)3WUDS®440
affinity beads (ChromoTek®) and the indicated amounts of ATP, ADP (Sigma-Aldrich®) or441
$73Ȗ6-HQD%LRVFLHQFHIRUKDW&ZKLOHHQGRYHUHQGPL[LQJ$OWHUQDWLYHO\FHOOO\VDWHV442
ZHUH LQFXEDWHG ZLWK  ȝJ SRO\FORQDO 8$3 DQWLERG\ IRU  K DW & ZKLOH HQGRYHUHQG443
mixing, before addition of Protein A agarose beads (Roche) for another 2 h. Where indicated,444
small molecule inhibitors were added in DMSO or EtOH, yielding a total of 0.1% DMSO or445
0.5% EtOH per immunoprecipitation, which was also supplemented in all control446
precipitations. Beads were washed 4 times in ice-cold modified RIPA buffer and proteins were447
eluted in Laemmli buffer before analysis by western blotting as previously described53.448
449
Immunoblotting. Western blots were performed as previously described33. Briefly, protein450
samples were run on 10-12% polyacrylamide gels and transferred to nitrocellulose HybondTM-451
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C (GE Healthcare) membranes via tank blotting. Membranes were blocked with TBS + 0.1%452
v/v Tween® 20 and 5% w/v dried skimmed milk powder. Membranes were probed with relevant453
primary and secondary HRP-conjugated IgG antibodies (Dako), treated with EZ-ECL454
(Geneflow), and exposed to Hyperfilm ECLTM (GE Healthcare).455
456
Recombinant protein expression. Recombinant GST and GST-UAP56 were expressed in457
E.coli BL-21 at 30°C over night and purified as described previously13,28,54. Proteins were458
eluted from the beads using 50 mM Tris/HCl (pH 7.6) with 10 mM reduced Glutathione and459
then further purified by buffer exchange using PD midiTrapTM G-25 columns (GE Healthcare)460
and 50 mM Tris/HCl, 50 mM KCl, 2 mM MgCl2; pH 7.6).461
462
Microscale thermophoresis. Microscale thermophoresis (MST) was carried out on a463
Monolith NT.115 Microscale Thermophoresis device using standard treated capillaries464
(NanoTemper Technologies). Recombinant GST-UAP56 was labelled with FITC (Sigma-465
Aldrich®) according to the manufacturer’s instructions. Labelling reagent was removed by466
buffer-exchange chromatography using ZebaTM Spin Desalting Columns following the467
manufacturer’s instructions and eluted into 20 mM HEPES (pH 7.4) with 2 mM MgCl2. The468
concentration of labelled protein was used between 100 and 500 nM by diluting labelled469
protein in 20 mM HEPES (pH 7.4) with 2 mM MgCl2. LED power was used at 10-60%. All470
reactions were performed at 37°C. Equal amounts of labelled protein were titrated by471
CCT018159 diluted in DMSO and 20 mM HEPES (pH7.4) with 2 mM MgCl2 in a 1:1 series472
dilution starting with 4.5 mM CCT018159, such that the final concentration of DMSO was 20%473
(v/v) in all capillaries. Curve fitting and KD determination was performed using the NTanalysis474
software (NanoTemper Technologies) in the Thermophoresis mode. All replicates were of475
biological nature.476
477
Cell viability assay. Cell viability was measured in HEK-293T, TREx BCBL1-Rta and HFF478
cells using an MTS-based CellTiter 96® AQueous One Solution Cell Proliferation Assay479
(Promega), following the manufacturer’s instructions. HEK-293T cells were seeded at a480
concentration of 0.5×106 cells/ml and HFF cells at 1×105 cells/ml, 24 h before treatment with481
small molecule inhibitors. TREx BCBL1-Rta cells were seeded at 1×106 cells/ml and treated482
immediately. The indicated inhibitor concentrations were delivered in DMSO (0.1% of total483
volume), which was also added to all control wells, and incubated for 24 or 72 h, before cell484
viability was assessed. All replicates were of biological nature.485
486
Apoptosis assay. Apoptotic and necrotic cells were stained using the Annexin-V-FLUOS487
Staining Kit and protocol from Roche. In brief, TREx BCBL1-Rta cells were treated with488
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DMSO, CCT018159 or 17-DMAG for 72 h, before they were washed and incubated in a489
HEPES buffer containing Annexin-V-Fluorescein and propidium iodide to label apoptotic and490
necrotic cells. Cells were analyzed using a flow cytometer. All replicates were of biological491
nature.492
493
Immunofluorecence. Cell fixation and staining was performed as previously described55.494
Briefly, HEK-293T cells were grown on sterilized glass coverslips treated with Poly-L-Lysine495
before being transfected. After 24 h cells were washed in PBS and fixed in PBS containing496
4% (v/v) paraformaldehyde for 10 minutes, washed twice in PBS and permeabilized using497
PBS containing 1% Triton X-100 for 10 minutes. Coverslips were then incubated with498
appropriate primary and secondary antibodies for 1 hour each at 37°C before being mounted499
onto microscope slides using Vectashield® with DAPI. Slides were visualized on a Zeiss LSM500
700 laser scanning confocal microscope and images analyzed using Zen® 2011 (Zeiss).501
502
KSHV replication assay. To determine the viral-DNA load, TREx BCBL1-Rta cells were503
harvested 72 h after reactivation of viral lytic replication. Total DNA was isolated using the504
QIAamp DNA mini kit (QIAGEN) following the manufacturer’s instructions and quantified by505
UV spectrophotometry. Quantification of viral DNA copy numbers was performed using a506
Rotor-Gene 6000 Real-Time PCR machine (QIAGEN). Amplification was performed in 20 µl507
reaction volumes with 40 ng template DNA using SensiMixTMPlus SYBR qPCR reactions508
(Bioline), as per manufacturer's instructions, with a standard 3-step melt program (95°C for 15509
seconds, 60°C for 30 seconds, 72°C for 20 seconds). Amplifications of the viral gene ORF57510
were carried out using the forward primer 5’-TGTCAGTGGTGGACCTGAC and reverse primer511
5’-GTGGTCGTTGAGGGCAATG. The viral gene ORF47 was amplified using the forward512
primer 5’-CGCGGTCGTTCGAAGATTGGG and reverse primer 5’-513
CGAGTCTGACTTCCGCTAACA. GAPDH was amplified using the forward primer 5’-514
GCCATAATCAAGCGTACTGG and reverse primer 5’-GCAGACAAATATTGCGGTGT.515
Quantitative analysis for viral DNA levels with GAPDH as internal control was carried out using516
the comparative CT method as previously described38. Replicates were of biological nature,517
with each used for 2 technical repeats.518
519
Primary HSV-1 infection. A MOI of 0.001 was used for primary infection of 2×105 HFF with520
HSV-1. Following 1 h incubation of cells with virus, cells were washed twice with PBS, followed521
by addition of growth media (for analysis of infectious HSV-1 virion production) or plaque agar522
(for HSV-1 plaque assays of primary infection). Both growth media and plaque agar were523
supplemented with small molecule inhibitor concentrations or DMSO (at a final concentration524
of 0.1% DMSO in all wells).525
18
526
Infectious HSV-1 virion production. After 72 h primary HSV-1 infection, cell supernatants527
were diluted 1:10-10,000 with new growth media and incubated on 2×105 naïve HFF cells. Re-528
infection was analyzed by plaque assay (below) or using flow cytometry. For the latter, cells529
were incubated with infectious virions from a primary infection for 24 h, fixed using PBS with530
4% (v/v) paraformaldehyde and washed twice again with PBS. As a recombinant virus531
expressing GFP was used, all HSV-1-infected cells were quantified via fluorescence using the532
BD LSRFortessa flow cytometer (BD Biosciences) on the FITC channel. All replicates were of533
biological nature.534
535
HSV-1 plaque assay. Plaque assays were performed after primary infection or re-infection of536
naïve HFF cells with HSV-1, as described above. After 1 h incubation of 2×105 HFF cells with537
HSV-1, cells were washed twice with PBS and overlaid with plaque agar (1:1 dilution of growth538
media with 2% (w/v) molten agarose, tempered to 37°C). Small molecule inhibitors were539
added to plaque agar during primary HSV-1 infections, re-infection for assessment of540
infectious HSV-1 virion production was performed without additional inhibitors. The agarose541
was removed after 96 h, cells washed once with PBS, fixed 10 min with 4% (v/v)542
paraformaldehyde and stained using 0.5% (w/v) crystal violet stain. Viral plaques were543
counted by eye. All replicates were of biological nature.544
Primary HCMV infection. A MOI of 0.08 and 0.008 was used for primary infection of 2×105545
HFF with HCMV. Following 1 h incubation of cells with virus, the growth media was546
supplemented with small molecule inhibitor concentrations or DMSO (at a final concentration547
of 0.1% DMSO in all wells).548
Infectious HCMV virion production. After 168 h primary HCMV infection, HFF cell549
supernatants were diluted 1:10 and 1:100 (for initial infection with an MOI of 0.08) or 1:10 (for550
initial infection with an MOI of 0.008) with new growth media and incubated on 2×105 naïve551
HFF cells for 20 h. Re-infection rates were measured by quantitative qPCR. For this, total DNA552
was isolated using the QIAamp DNA mini kit (QIAGEN) following the manufacturer’s553
instructions and quantified by UV spectrophotometry. Quantification of viral DNA copy554
numbers was performed using a Rotor-Gene 6000 Real-Time PCR machine (QIAGEN).555
Amplification was performed in 20 µl reaction volumes with 40 ng template DNA using556
SensiMixTMPlus SYBR qPCR reactions (Bioline), as per manufacturer's instructions, with a557
standard 3-step melt program (95°C for 15 seconds, 60°C for 30 seconds, 72°C for 20558
seconds). Amplifications of the viral gene UL69 were carried out using the forward primer 5’-559
TCGGTGGGATGAATTTGGTC and reverse primer 5’-CATGATAGCGTACTGTCCCTTC.560
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GAPDH was amplified using the forward primer 5’-GCCATAATCAAGCGTACTGG and561
reverse primer 5’-GCAGACAAATATTGCGGTGT. Quantitative analysis for viral DNA levels562
with GAPDH as internal control was carried out using the comparative CT method as563
previously described38. Replicates were of biological nature, with samples from one564
concentration series used for a control technical repeat.565
566
567
Synthesis and characterization of compounds.568
Compound 3 and Compound 4 were synthesized according to the methods described below.569
570
All reactions were carried out under a normal atmosphere and were stirred with a magnetic571
stirrer unless otherwise stated. All reagents were obtained from commercial sources and were572
used without further purification. Anhydrous solvents were dried by passing through aluminium573
oxide.574
Analytical thin-layer chromatography (TLC) was performed on aluminium pre-coated silica gel575
plates (254 µm) supplied by Merck chemicals and visualised by ultraviolet light (254 nm).576
Preparative flash column chromatography was carried out using Thomson Single Step pre-577
packed silica cartridges (4-25 g) on a Biotage Isolera Flash Purification system, or dry flash578
vacuum chromatography using 43-65 µm silica. High-resolution mass spectrometry was579
carried out using a VG Autospec mass spectrometer, operating at 70 eV, using electron spray580
ionisation (ES+), correct to four decimal places. Analytical high performance liquid581
chromatography (HPLC) was performed on an Agilent 1290 Inifinity Series equipped with a582
UV detector and Hyperprep C-18 column with a gradient of acetonitrile and water (5-95%) and583
0.1% TFA, at a flow rate of 0.5 cm3min-1 over a period of five minutes.584
Proton (1H) and carbon (13C) NMR spectra were recorded on a 300 / 75 MHz Bruker DPX300585
or a 500 / 125 MHz Bruker Advance 500 fourier transform spectrometer as indicated. Chemical586
VKLIWVįDUHUHSRUWHGLQSDUWVSHUPLOOLRQSSPDQGDUHUHSRUWHGZLWKUHIHUHQFHWRWKHUHVLGXDO587
solvent peak. Samples were prepared in either deuterated chloroform (CDCl3) or deuterated588
dimethylsulfoxide (DMSO-d6), as indicated. Multiplicities are reported with coupling constants589
(J) in Hertz and are uncorrected. Spectra were assigned with the aid of two-dimensional590
correlation spectroscopy (2D-COSY), performed on the same equipment as detailed above.591
Infra-red spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer.592
Vibrational frequencies are reported in wavenumbers (cm-1). Melting points were recorded on593
a Griffin melting point apparatus and are reported uncorrected.594
595
Compound 3 was synthesized in three steps from commercially available reagents:596
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1-(5-Ethyl-2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone597
To a vessel containing 4-ethylresorcinol (2.20 g; 16.0 mmol; 1.0 eq.) and 4-598
methoxyphenylacetic acid (2.64 g; 16.0 mmol; 1.0 eq.) was added boron trifluoride diethyl599
etherate (10 mL 0.08 mol; 5.0 eq.) and resulting slurry was heated to 90°C for 2 hours with600
stirring, then allowed to cool. The reaction mixture was then poured slowly over sodium601
acetate solution (10% w/v aq.; 100 mL) and stirred for 1 hour. The resulting mixture was602
extracted with ethyl acetate (2x50 mL), the organics combined and then washed with water603
(50 mL) then with brine (50 mL), dried (MgSO4) then concentrated to dryness. Purification of604
the residue via flash silica chromatography (0-15% methanol – dichloromethane) yielded the605
title compound as a pale orange solid (1.62 g; 5.66 mmol; 36%). 1H NMR (300 MHz, DMSO-606
d6):įV+&HCC(O)), 7.21 (d, J = 9.0 Hz, 2H, CHCHCOMe), 6.87 (d, J = 9.0 Hz, 2H,607
CHCOMe), 6.30 (s, 1H, C(OH)CHC(OH)), 4.22 (s, 2H, C(O)CH2), 3.74-3.70 (m, 4H, CH2CH3608
and Both OH), 2.08 (s, 3H, OCH3), 1.12 (t, J = 7.5 Hz, 3H, CH2CH3) ppm; 13C NMR (75 MHz,609
DMSO-d6):į610
30.65, 22.0, 14.2 ppm; m/z (ES+): Found: 287.1279 (M+H)+, C17H19O4 requires 287.1279;611
HPLC: RT = 3.27 min (100%); TLC: Rf = 1.00 (EtOAc); IR: vmax/cm-1 (solid): 3281, 2972,612
1719, 1613, 1512, 1418; M.pt: 86-88°C.613
6-Ethyl-7-hydroxy-3-(4-methoxyphenyl)-2-methyl-4H-chromen-4-one614
To a slurry of 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone (0.7g; 2.45mmol;615
1.0 eq.) and potassium carbonate (0.33g; 2.45mmol; 1.0 eq.) in N,N-dimethylformamide616
(10cm3) was added acetic anhydride (1cm3; 10.0mmol; 4.0 eq.) and resulting mixture was617
heated to 115°C with stirring for 2 hours, then allowed to cool. The reaction mixture was then618
poured on to water (100cm3) and the resulting precipitate was collected via filtration. The solid619
was then washed with water (50cm3) then with diethyl ether (2x20cm3), yielding the title620
compound as an off-white solid (316mg; 1.02mmol; 42%). 1H NMR (300 MHz, DMSO-d6):į621
7.94 (s, 1H, CHCC(O)), 7.17 (d, J = 9.0 Hz, 2H, CHCHCOMe), 6.98 (d, J = 9.0 Hz, 2H,622
CHCOMe), 6.84 (s, 1H, C(OH)CH), 3.79 (s, 3H, OCH3 H-12), 2.62 (q, J = 7.5 Hz, 2H, CH2CH3),623
2.23 (s, 3H, CCH3), 1.17 (t, J = 7.5 Hz, 3H, CH2CH3) ppm; 13C NMR (75 MHz, DMSO-d6):į624
174.9, 162.1, 160.5, 158.4, 155.3, 131.7, 129.6, 125.5, 124.8, 121.6, 115.1, 113.4, 101.1,625
79.8, 55.0, 22.3, 19.1, 13.8 ppm; m/z (ES+): Found: 333.1090 (M+Na)+, C19H18O4Na requires626
333.1090; HPLC: RT = 2.89 min (100%); TLC: Rf = 0.931 (EtOAc); IR: vmax/cm-1 (solid): 3093,627
2965, 1622, 1564, 1390; M.pt: >250°C.628
4-Ethyl-6-(4-(4-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl)benzene-1,3-diol (Compound629
3)630
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To a solution of 6-ethyl-7-hydroxy-3-(4-methoxyphenyl)-2-methyl-4H-chromen-4-one (200mg;631
0.65mmol; 1.0 eq.) in ethanol (5cm3) was added hydrazine hydrate (0.63cm3; 12.9mmol; 20.0632
eq.) and resulting solution was heated to reflux overnight with stirring. The reaction mixture633
was allowed to cool, then water was added (10cm3) and mixture was stirred for a further 15634
mins. The resulting precipitate was then collected via filtration, yielding the title compound as635
an off-white powder (171mg; 0.53mmol; 82%). 1H NMR (500 MHz, DMSO-d6):įGJ =636
9.0, 2H, CHCHCOMe), 6.95 (d, J = 9.0 Hz, 2H, CHCOMe), 6.69 (s, 1H, CH3CH2CCH), 6.32637
(s, 1H, C(OH)CHC(OH)), 3.75 (s, 3H, H-CCH3), 3.33 (s, 3H, OCH3), 2.18 (q, J = 7.5 Hz, 2H,638
CH2CH3), 0.78 (t, J = 7.5 Hz, 3H, CH2CH3) ppm; 13C NMR (75MHz, DMSO-d6):į639
154.6, 139.3, 130.9, 128.1, 126.3, 119.9, 115.9, 113.8, 108.5, 102.4, 55.0, 21.4, 13.6, 10.3640
ppm; m/z (ES+): Found: 325.1553 (M+H)+, C19H21N2O3 requires 325.1547; HPLC: RT = 2.38641
min (100%); TLC: Rf = 0.897 (EtOAc); IR: vmax/cm-1 (solid): 3384, 3331, 2961, 1612, 1519;642
M.pt: 141-143°C.643
644
Compound 4 was synthesized in two steps from commercially available reagents:645
6-Ethyl-7-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromene-2-carboxylic acid646
A solution of 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone (0.5g; 1.75mmol;647
1.0 eq.) in pyridine (10cm3) was cooled to 0°C, then methyl chlorooxoacetate (1.14cm3;648
7.00mmol; 4.0 eq.) was added dropwise with stirring. Dichloromethane (20cm3) was then649
added to the resulting slurry and poured on to HCl (1M aq.; 30cm3). The organics were650
separated then the aqueous layer extracted with dichloromethane (2x303) and organics were651
combined, washed with brine (3x30cm3), dried (MgSO4), and concentrated to dryness to give652
an orange residue. This was taken up in methanol (10cm3) and HCl (1M aq.; 10cm3) was653
added and solution was heated to reflux with stirring for 4 hours. The reaction mixture was654
concentrated to dryness and methanol (10cm3) and sodium bicarbonate solution (sat. aq.;655
20cm3) was added to the residue and heated to 65°C with stirring overnight. Resulting solution656
was allowed to cool and HCl (1M aq.) was added until solution reached pH 1 (pH paper).657
Resulting precipitate was collected via filtration and washed with a little water, then a little658
diethyl ether to give the title compound as an off-white powder (127mg; 0.37mmol; 21%). 1H659
NMR (500 MHz, DMSO-d6):įV+&HCC(O)), 7.26 (d, J = 8.5 Hz, 2H, CH2CH2OMe),660
6.94 (d, J = 8.5 Hz, 2H, CHCOMe), 6.91 (s, 1H, C(OH)CH), 3.77 (s, 3H, OCH3), 2.62 (q, J =661
7.5, 2H, CH2CH3), 1.17 (t, J = 7.5 Hz, 3H, CH2CH3) ppm; 13C NMR (75 MHz, DMSO-d6):į662
175.5, 162.7, 161.3, 158.9, 155.0, 131.2, 130.6, 124.8, 124.0, 115.5, 113.2, 101.4, 55.0, 22.3,663
13.7 ppm; m/z (ES+): Found: 341.1010 (M+H)+, C19H17O6 requires 341.1020; HPLC: RT =664
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2.42 min (100%); TLC: Rf = 0.103 (EtOAc); IR: vmax/cm-1 (solid): 3134, 1728, 1573, 1513,665
1412; M.pt: >250°C.666
3-(5-Ethyl-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazole-5-carboxylic acid667
(Compound 4)668
To a solution of 6-ethyl-7-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromene-2-carboxylic acid669
(100mg; 0.29mmol; 1.0 eq.) in ethanol (5cm3) was added hydrazine hydrate (0.03cm3;670
0.59mmol; 2.0 eq.) and resulting mixture was heated to reflux with stirring overnight. The671
reaction mixture was allowed to cool and poured on to HCl (1M aq.; 20cm3), then resulting672
mixture was extracted with diethyl ether (3x20cm3). The organics were combined and washed673
with HCl (1M aq.; 40cm3), dried (MgSO4) and concentrated to dryness, yielding the title674
compound as a yellow foam (58mg; 0.164mmol; 56%). 1H NMR (300 MHz, DMSO-d6):į675
(s, 1H, CO2H), 9.31 (s, 1H, pyrazole NH), 7.12 (d, J = 9.0 Hz, 2H, CHCHCOMe), 6.84 (d, J =676
9.0 Hz, 2H, CHCOMe), 6.56 (s, 1H, CH3CH2CCH), 6.37 (s, 1H, C(OH)CHC(OH)), 3.73 (s, 3H,677
OCH3), 2.24 (q, J = 7.5 Hz, 2H, CH2CH3), 0.85 (t, J = 7.5 Hz, 3H, CH2CH3) ppm; 13C NMR (75678
MHz, DMSO-d6): į          679
116.9, 104.7, 19.30, 43.1, 32.1, 30.4, ppm; m/z (ES+): Found: 355.1294 (M+H)+, C19H19N2O5680
requires 355.1294; HPLC: RT = 2.23 min (100%); TLC: Rf = 0.207 (EtOAc); IR: vmax/cm-1681
(solid): 3283, 2964, 1702, 1613, 1513, 1460; M.pt: 214-216°C.682
683
CCT018159, Compound 1 and 2 were purchased from commercial vendors (C2 from Tocris684
and Compound 1 and 2 from Enamine).685
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Figure Legends844
845
Figure 1: ATP-cycle dependent remodeling of hTREX affects ORF57-mediated vRNP846
formation. (a) Immunoprecipitations of GFP or GFP-UAP56, co-expressed in the absence or847
presence of mCherry-ORF57. Precipitations were performed with HEK-293T whole cell848
lysates (Input) in the absence of any additional nucleotides or in presence of 1.25 mM ATP or849
P0$73Ȗ66DPSOHVZHUHDQDO\]HGE\ZHVWHUQEORWWLQJXVLQJWKHLQGLFDWHGDQWLERGLHV850
(b) Quantification of 4 independent immunoprecipitations (performed with mCherry-ORF57,851
as shown in a, or Myc-ORF57). Values are averages, error bars present SD, n = 4. p < 0.01852
RUSHIIHFWRI$73RU$73Ȗ6FRPSDUHGWRXQWUHDWHGXVLQJDQXQSDLUHGt test.853
(c) Immunoprecipitations of GFP-UAP56 after co-expression with mCherry-ORF57.854
Precipitations were performed with HEK-293T whole cell lysate (Input) in the absence of any855
additional nucleotides or with increasing concentrations of nucleotides, as indicated. Samples856
were analyzed by western blotting using the indicated antibodies. (d) Quantification of 3857
LQGHSHQGHQW LPPXQRSUHFLSLWDWLRQV DW FRQFHQWUDWLRQV RI  RU  P0 $73 $73Ȗ6 RU858
ADP). Values are averages, error bars present SD, n = 3. p < 0.05 (*), p < 0.01 (**) or p <859
  HIIHFW RI $73 RU $73Ȗ6 FRPSDUHG WR XQWUHDWHG XVLQJ DQ XQSDLUHG t test. (e)860
Schematic representation of ATP-cycle dependent remodeling of central hTREX components861
and the ORF57-mediated vRNP. The proposed model is based on the immunoprecipitations862
shown in a-d.863
864
Figure 2: Identification of UAP56-targeted ATPase inhibitor. (a) Chemical structure of865
UAP56 ATPase inhibitor CCT018159, identified through in silico high-throughput and in vitro866
27
screening against UAP56 ATPase activity. (b) Predicted binding mode of CCT018159 (orange867
sticks) to the ATP-binding pocket of UAP56. Docking routine performed using AutoDock4868
6FULSSV 5HVHDUFK ,QVWLWXWH DQG WKH 8$3ǻ 0J$'3 FRPSOH[ 3'% ,' ;7- 3RODU869
interactions are shown as dotted lines. (c) Surface potential representation of b, showing the870
occupancy of the AT(D)P binding site by CCT018159 by overlay with ADP (purple lines) from871
the co-crystallised UAP56:ADP structure. Docking routine performed using AutoDock4872
6FULSSV 5HVHDUFK ,QVWLWXWH DQG WKH 8$3ǻ 0J$'3 FRPSOH[ 3'% ,' ;7- d) 2-873
dimensional representation of CCT018159 in the UAP56 binding site. All key interacting874
residues are highlighted and hydrogen bonds are shown as dashed lines and a S-stack875
interaction as waves. (e) IC50 of CCT018159 for UAP56 ATP-hydrolysis. In vitro ATPase876
activity of purified recombinant UAP56 was measured in the presence of increasing877
concentrations of CCT018159. Values are averages from 7 assays performed after878
independent protein purification processes of recombinant protein, n = 21, error bars display879
the SD. The IC50 was determined using non-linear regression with a variable slope (four-880
parameter logistic curve). (f) Microscale thermophoresis binding curves for binding of881
CCT018159 and ATP to UAP56. Data are plotted for normalized signal change as a function882
of CCT018159 or ATP concentration, respectively. Values are averages, error bars present883
the SD, n = 3. (g) ADP-displacement from UAP56 by CCT018159. Free ADP was measured884
after increasing concentrations of CCT018159 were added to ADP-bound purified885
recombinant UAP56. Values are averages, error bars present SD, n = 3.886
887
Figure 3: CCT018159 disrupts formation and function of the vRNP, but not of the888
endogenous hTREX complex. (a) Cell viability of HEK-293T cells in the presence of889
increasing amounts of CCT018159 as measured by MTS assay. Data was normalized to890
DMSO treated control cells. Values are averages, n = 5, error bars display SD. The CC50 was891
determined using non-linear regression with a variable slope (four-parameter logistic curve).892
(b) Immunoprecipitations of endogenous UAP56 in GFP or ORF57-GFP expressing cells.893
HEK-293T cells were treated with indicated amounts of CCT018159 6 h after transfection.894
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Precipitations were performed with whole cell lysates (Input) in the absence or in presence of895
the indicated CCT018159 concentration range or DMSO control. Samples were analyzed by896
western blotting using the indicated antibodies. Results are representative of 3 independent897
repeats at varying concentrations. (c) HEK-293T cells co-expressing GFP or ORF57-GFP and898
the intronless reporter construct ORF47 were treated with DMSO or 2.5 µM CCT018159. qRT-899
PCR was performed after subcellular fractionation. ORF47 transcript levels were normalized900
WR*$3'+DQGWKHUHODWLYHLQFUHDVHFDOFXODWHGXVLQJWKHǻǻ&7PHWKRG9DOXHVDUHDYHUDJHV901
n = 3, error bars display SD, p < 0.05 (*) or p < 0.001 (***), effect CCT018159 compared to902
DMSO treated, using an unpaired t test. (d) HEK-293T cells expressing GFP or ORF57-GFP903
were treated with DMSO or 2.5 µM CCT018159, as indicated. A fluorescently labelled904
oligo(dT) probe was used to detect poly(A) RNA, DAPI visualizes the nucleus. Arrows indicate905
localization of poly(A) RNA. Scale bar = 20 µm. Images representative of 4 independent906
experiments. (e) Quantification of cells with nuclear mRNA retention in GFP or ORF57-GFP907
transfected cells, treated with DMSO or CCT018159, as indicated. Values are averages of 4908
independent experiments (GFP + DMSO and ORF57-GFP + CCT018159) or 6 independent909
experiments (ORF57-GFP + DMSO), error bars present the SD. A total of 32 GFP transfected910
and 76 ORF57-GFP transfected cells (for each treatment) were counted. p < 0.001, effect of911
DMSO compared to CCT018159 treated, using a Fisher’s exact test.912
913
Figure 4: Disruption of virus lytic replication and infectious virion production by914
CCT018159. (a, b) Viability of TREx BCBL1-Rta cells in the presence of CCT018159 at 24915
and 72 h, determined by MTS assay. (c) Expression of viral late protein mCP in TREx BCBL1-916
Rta cells after normalization to GAPDH, as determined by western blotting using mCP- and917
GAPDH-specific antibodies. Cell viability values from a are shown in comparison. (d) Viral918
load in TREx BCBL1-Rta cells in response to CCT018159 was measured by qPCR, 72 h after919
induction of KSHV lytic replication. Viral DNA was normalized to GAPDH and the relative920
GHFUHDVH FRPSDUHG WR '062 WUHDWHG VDPSOHV FDOFXODWHG XVLQJ WKH ǻǻ&7 PHWKRG &HOO921
viability values from b are shown in comparison. (e) Production of infectious KSHV virions was922
29
determined by re-infection of HEK-293T cells, 72 h after induction of lytic replication in TREx923
BCBL1-Rta cells and treatment with 2.5 µM CCT018159. Viral mRNA levels were determined924
by qRT-PCR and normalized to GAPDH, and are shown as fold change compared to DMSO925
treated controls. p < 0.01 using an unpaired t test. For all figures: Values are averages, error926
bars present SD. EC50 and CC50 values were determined using non-linear regression with a927
variable slope (four-parameter logistic curve). (a, b) n = 5, (c, d) n = 4, (e) n = 6.928
929
Table 1: Close structural analogues of CCT018159 and their effect on UAP56 ATPase930
activity, cell viability and KSHV lytic replication. The schematic shows the common931
structure of CCT018159 and its close structural analogues. Functional groups that differ932
between the analogues are indicated, as well as the effect of these changes on ATPase933
activity of purified UAP56, cell viability at 24 and 72 h, viral late protein expression and viral934
ORDGRI75([%&%/5WDFHOOV9DOXHVDUHPHDQVHPQIRUDOOH[SHULPHQWV'XHWR935
minimal effect of Compound 4 in most biological assays, not all data points were found to936
converge or present a trend that could be displayed by nonlinear regression. IC50, CC50 and937
EC50 values outside of the tested range had to be extrapolated from the obtained data.938
939
)LJXUH  ,QKLELWLRQ RI Į DQG ȕKHUSHVYLUXV UHSOLFDWLRQ E\ &&7 (a, b)940
Immunoprecipitations of endogenous UAP56 in (a) GFP and ICP27-GFP or (b) GFP and941
UL69-GFP expressing cells. HEK-293T cells were treated with indicated amounts of942
CCT018159, 6 h after transfection. Precipitations were performed with whole cell lysates943
(Input) in the absence or in presence of the indicated CCT018159 concentration range or944
DMSO control. Samples were analyzed by western blotting using the indicated antibodies.945
Results are representative of 3 independent repeats at varying concentrations. (c, d) Viability946
of HFF cells in the presence of CCT018159 at 72 and 168 h, determined by MTS assay.947
Values are averages, error bars present SD, n = 5. CC50 values were determined using non-948
linear regression with a variable slope (four-parameter logistic curve). (e) Plaque assay in the949
absence or presence of increasing amounts of CCT018159, 120 h after primary infection with950
30
HSV-1. Scale bar = 2 cm. Results are representative of 2 independent repeats. (f) Production951
of infectious HSV-1 virions was measured by re-infection of HFF cells, 72 h after primary952
infection and treatment with CCT018159. Supernatants of primary infected cells were diluted953
1:100 before being added to fresh HFF cells. The percentage of infected cells was determined954
E\IORZF\WRPHWU\DVVHVVLQJFHOOVg) HSV-1 infectious virion production was also955
assessed by plaque assay. Virion containing supernatants were used to reinfect HFF cells,956
72 h after primary infection and treatment with CCT018159. Plaques were counted 120 h after957
re-infection. Values are averages, error bars present SD, n = 4. (h) HCMV infectious virion958
production was assessed by re-infection assay, 168 h after initial infection of HFF cells and959
treatment with CCT018159. Levels of re-infection were determined by qPCR, with viral DNA960
levels normalized to GAPDH. The percentage of infected cells is shown relative to DMSO961
treated control cells. Values are averages, error bars present SD, n = 3.962
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assay)
CC50 24 h (µM)
(Cell viability)
CC50 72 h (µM)
(Cell viability)
EC50 24 h (µM)
(mCP
expression)
EC50 72 h (µM)
(Viral load)
CCT018159 Me -OCH2CH2O- Et 64.3 ± 2.5 21.1 ± 1.6 16.6 ± 1.1 0.6 ± 0.1 1.1 ± 0.1
Cmpd. 1 Me H H Et 127.4 ± 8.4 28.9 ± 1.7 7.6 ± 0.1 3.1 ± 0.2 1.5 ± 0.1
Cmpd. 2 Me -OCH2CH2O- H 309 ± 26.4 46.1 ± 3.8 25.1 ± 2.4 2.4 ± 0.3 5.1 ± 0.4
Cmpd. 3 Me OMe H Et 88.7 ± 7.9 27.9 ± 2.7 14.7 ± 0.5 2.4 ± 0.4 2.7 ± 0.2
Cmpd. 4 CO2H OMe H Et > 1000* ~ 820* > 1000* > 1000* 138.1 ± 45.2*
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